Literature DB >> 1667489

[Relation between the dosage of methimazole and its intrathyroidal concentrations].

G Huang.   

Abstract

Intrathyroidal concentrations of methimazole (MMI) were measured by means of high-performance liquid chromatography in 46 patients with Graves' disease who had undergone thyroidectomy. In this experiment, the dose of the drug varied from 5 mg/day to 40 mg/day, and the interval between the last dose and surgery ranged from 2 to 26 hours, and the mode of drug administration varied from a single dose to four divided doses. With dose of MMI from 5 to 15 mg/day, intrathyroid levels of MMI increased with increasing dose, but without significant increase when the dose was above 15 mg/day. There was no difference between patients taking the drug in divided doses and those taking it in one single dose of the same amount, or between patients taking the final dose 2 hours before thyroid excision aud those taking it 26 hours before excision. Our results indicate a saturable uptake mechanism for MMI by the thyroid, and MMI 15 mg/day is the most satisfactory dose for treating hyperthyroidism. The intrathyroidal concentrations are maintained for 26 hours at least, and the single daily dose of MMI is effective and reasonable for treatment of Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1667489

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Za Zhi        ISSN: 0376-2491


  2 in total

1.  A patient-specific treatment model for Graves' hyperthyroidism.

Authors:  Balamurugan Pandiyan; Stephen J Merrill; Flavia Di Bari; Alessandro Antonelli; Salvatore Benvenga
Journal:  Theor Biol Med Model       Date:  2018-01-09       Impact factor: 2.432

2.  Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study.

Authors:  Sutin Sriussadaporn; Wanwaroon Pumchumpol; Raweewan Lertwattanarak; Tada Kunavisarut
Journal:  Int J Endocrinol       Date:  2017-12-18       Impact factor: 3.257

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.